Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nexentis Technologies Inc. (NITO)
Meshek Sander Neve Yarak, IL, IL
Nexentis Technologies Inc. develops and operates an AI and data-driven computational biotech platform. It focuses on mitochondrial biology, precision oncology, and inflammatory metabolic diseases. The company biotechnology segment, driven by its proprietary MITOLINE discovery engine and structure-guided virtual screening workflows, is engaged in the discovery and development of small-molecule therapeutics targeting the mitochondrial SLC25 carrier family for resistant cancers and inflammatory metabolic disease indications. The company’s pipeline includes preclinical programs for oncology and metabolic-inflammation, with evidence supporting anti-tumor and anti-inflammatory activity in human-relevant systems. The renewable energy investments segment manages non-core, value-optimizing assets, including investments in solar energy projects across multiple european union countries, utilizing a ready to build business model. In addition, the company provides post-harvest treatment technologies for reducing pathogen contamination in fruits and vegetables. It serves customers in the biotechnology, pharmaceutical, and renewable energy sectors, as well as the agricultural industry. The company operates internationally, with a particular focus on the European Union and Israel. The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.09% | -9.00% | +8.01% | +463.29% | +59.50% | +164.88% | -53.79% | -97.61% | -99.83% | -99.19% | -99.39% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%-100.0% Q1'26: -100.0% (vs Q1'25)
-
EPS growth Chemicals: +11.7%+88.5% ★ Q1'26: -315.8% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%—
-
EBIT margin Chemicals: +7.1%—
-
ROIC Chemicals: +3.4%-40.5% Q1'26: -126.9% (vs Q1'25)
-
Share dilution Chemicals: +0.0%+674.7% Q1'26: +32.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×-0.15× Q1'26: -0.04× (vs Q1'25)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Investments Ltd. | 1.56M | 16.66% | 1.56M | — | 1.56M | — | CO | Israel | 2023-07-31 | ↗ |
| 2 | Foods, Inc. | 1.16M | 16.66% | 1.16M | — | 1.16M | — | CO | British Columbia, Canada | 2023-04-10 | ↗ |
| 3 | Reinhold | 688.4K | 6.14% | 113.3K | 688.4K | 113.3K | 688.4K | IN | Israel | 2020-10-15 | ↗ |
| 4 | Amir Uziel | 591.0K | 5.47% | 591.0K | — | 591.0K | — | IN | Israel | 2020-08-18 | ↗ |
| 5 | Ecology Ltd. | 98.9K | 3.52% | 98.9K | — | 98.9K | — | CO | Israel | 2022-02-14 | ↗ |
| 6 | Consulting & Management Services Ltd. (1) | 90.7K | 3.23% | 90.7K | — | 90.7K | — | CO | Israel | 2022-02-14 | ↗ |
| 7 | Shrem | 90.7K | 3.23% | 90.7K | — | 90.7K | — | IN | Israel | 2022-02-14 | ↗ |
| 8 | Gleb Fetisov | 86.0K | 5.90% | 86.0K | — | 86.0K | — | IN | Cyprus | 2024-02-01 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-09 | Zakai Shlomo | Officer | A-Award | A | Restricted Shares of Common Stock | 50,000 | 0.00 | — | 64,778 | I | ↗ |
| 2026-02-09 | Weiss Amitay | Director | A-Award | A | Restricted Shares of Common Stock | 116,286 | 0.00 | — | 129,144 | I | ↗ |
| 2026-02-09 | Palach David | Officer | A-Award | A | Restricted Shares of Common Stock | 100,000 | 0.00 | — | 129,144 | I | ↗ |
| 2026-02-09 | Barda Lital | Officer | A-Award | A | Restricted Shares of Common Stock | 50,000 | 0.00 | — | 64,370 | I | ↗ |
| 2025-10-20 | Silberman Alon | 10% Owner | — | — | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 454,127 | I | ↗ |
| 2025-10-20 | SciSparc Ltd. | 10% Owner | — | — | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 490,751 | D | ↗ |
| 2025-05-12 | Palach David | Officer | A-Award | A | Restricted Shares of Common Stock | 600,000 | 0.00 | — | 1,020,000 | I | ↗ |
| 2025-05-12 | Barda Lital | Officer | A-Award | A | Restricted Shares of Common Stock | 300,000 | 0.00 | — | 502,857 | I | ↗ |
| 2024-12-23 | Weiss Amitay | Director | A-Award | A | Restricted Shares of Common Stock | 350,000 | 0.00 | — | 450,000 | D | ↗ |
| 2024-12-23 | Sidi Liat | Director | A-Award | A | Restricted Shares of Common Stock | 50,000 | 0.00 | — | 50,000 | D | ↗ |
| 2024-12-23 | Rosenbloom Ronen | Director | P-Purchase | A | Restricted Shares of Common Stock | 50,000 | 0.00 | — | 64,500 | D | ↗ |
| 2024-12-23 | Kalifi Udi Ovadia | Director | A-Award | A | Restricted Shares of Common Stock | 50,000 | 0.00 | — | 68,457 | D | ↗ |
| 2024-12-23 | Itzhaik Asaf | Director | A-Award | A | Restricted Shares of Common Stock | 50,000 | 0.00 | — | 50,000 | D | ↗ |
| 2024-12-23 | Berenstein Israel Yakov | Director | A-Award | A | Restricted Shares of Common Stock | 50,000 | 0.00 | — | 64,500 | D | ↗ |
| 2024-12-23 | Arbib Eliahou | Director | A-Award | A | Restricted Shares of Common Stock | 50,000 | 0.00 | — | 64,500 | D | ↗ |
| 2024-09-12 | Palach David | Officer | A-Award | A | Restricted Shares of Common Stock | 320,000 | 0.00 | — | 420,000 | — | ↗ |
| 2024-09-12 | Barda Lital | Officer | A-Award | A | Restricted Shares of Common Stock | 160,000 | 0.00 | — | 202,857 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Palach | Chief Executive Officer | 106.1K | male |
| Lital Barda | Chief Financial Officer, Financial Controller, Treasurer & Secretary | 91.6K | female |
| Galit Kenigsberg | Head of Sustainability Operations of scientific advisory board | — | female |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NITO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
